Pathology: breast cancer - adjuvant; la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1);
| breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | ||
| PENELOPE-B, 2021 | KCSG-BR15-10, 2019 | PENELOPE-B, 2021 | ||
| palbociclib plus endocrine therapy | 3 | T1 | T1 | T1 |
| endocrine therapy | 0 | T0 | T0 | |
| capecitabine | 0 | T0 |